| 1) river of many solid tumors including lung cancer. |
| 2) ival in patients with resected colorectal cancer. |
| 3) herapies, which stopped working for their cancer. |
| 4) plastic drug candidates for human gastric cancer. |
| 5) oved access and care to our patients with cancer. |
| 6) bit chronic inflammation, known causes of cancer. |
| 7) ore effective epigenetic therapy for lung cancer. |
| 8) class of anticancer agents to treat lung cancer. |
| 9) n the process of caring for patients with cancer. |
| 10) rgets and prognostic markers for cervical cancer. |
| 11) immune and inflammatory pathways in lung cancer. |
| 12) being endometrial, ovarian, and cervical cancer. |
| 13) ing on ovarian, endometrial, and cervical cancer. |
| 14) een studied intensively in the context of cancer. |
| 15) d palliative care of PWIDD diagnosed with cancer. |
| 16) ghout life, including type 2 diabetes and cancer. |
| 17) cross common molecular subtypes of breast cancer. |
| 18) etection and early treatment for cervical cancer. |
| 19) an attractive target for the treatment of cancer. |
| 20) titutions increased awareness of cervical cancer. |
| 21) evastating manifestation of many types of cancer. |
| 22) ical constructs in children and AYAs with cancer. |
| 23) g of tumor suppressor genes in human lung cancer. |
| 24) ul effects thereby treating or preventing cancer. |
| 25) mpact in patients with oral or pharyngeal cancer. |
| 26) than pain generated by any other form of cancer. |
| 27) strointestinal cancers such as pancreatic cancer. |
| 28) es for neoadjuvant approaches to T4 colon cancer. |
| 29) their mediating effects between UGSs and cancer. |
| 30) a viable diagnostic biomarker for ovarian cancer. |
| 31) o the initiation and progression of liver cancer. |
| 32) improve treatment strategies in cervical cancer. |
| 33) /lashes, cataracts, and predisposition to cancer. |
| |